DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Ulcerative Colitis (EU) 2013

TreatmentTrends® Ulcerative Colitis (UC) in the European five (EU5) is a report that covers the use of biologics for the treatment of UC in France, Germany, Italy, Spain and the UK. The report focuses on current and future use of UC treatments, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, and sales force performance for the total EU5 as well as by country.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Determine the typical patient load, diagnosis and prevalence of biologic treatment among gastroenterologists for UC

  • Understand how and why biologic use is expected to shift among gastroenterologists in the next six months for UC

  • Compare the current therapies in terms of UC market share (current and future) and highlight the leading obstacles to brand growth

  • Understand the unmet needs in the UC biologics market

  • Understand the attributes that gastroenterologists feel are most important with the various therapies used to treat patients with Ulcerative Colitis

  • Evaluate awareness of products in development and understand which product attributes will be most desirable in future biologic agents


Sample Frame & Methodology:

250 gastroenterologists will complete a 45- minute online quantitative survey -50 gastroenterologists from France -50 gastroenterologists from Germany -50 gastroenterologists from Italy -50 gastroenterologists from Spain -50 gastroenterologists from the UK

To qualify for participation, gastroenterologists must meet the following criteria:

- Board certified in gastroenterology

- In practice between 2 and 30 years

- Minimum of 25 UC patients under their personal management

- Minimum of 5 UC patients being treated with biologic agents


- Powerpoint decks to be published

- Complete set of frequency tables, summary statistics, and standard cross-tabulations

- Up to three proprietary questions answered per client in each wave

Product Coverage:

Appproved: Humira and Remicade

Off Label: Cimzia, Simponi and Tysabri

In development: Simponi (Golimumab), Vedolizumab and Tofacitinib

Related 2013 Reports:

- TreatmentTrends®: Ulcerative Colitis (US)

- TreatmentTrends®: Crohn’s Disease (US)

- TreatmentTrends®: Crohn’s Disease (EU)

Related 2012 Reports:

- TreatmentTrends®: Ulcerative Colitis (US)

- PatientTrends®: Ulcerative Colitis (US)

- TreatmentTrends®: Crohn’s Disease (US)

- PatientTrends®: Crohn’s Disease (US)

- ChartTrends®: Crohn’s Disease (US)